Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance-Reference-Cited by-同舟云学术

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance

Published:2018-01-03 Issue:10 Volume:142 Page:2139-2152
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Martin Claire A.¹,Cullinane Carleen¹²,Kirby Laura¹,Abuhammad Shatha¹²,Lelliott Emily J.¹²,Waldeck Kelly¹,Young Richard J.¹,Brajanovski Natalie¹,Cameron Donald P.¹,Walker Rachael¹,Sanij Elaine¹³,Poortinga Gretchen¹²⁴,Hannan Ross D.¹²⁵⁶⁷,Pearson Richard B.¹²⁵⁶,Hicks Rodney J.¹²,McArthur Grant A.¹²⁴,Sheppard Karen E.¹²⁵^ORCID

Affiliation:

1. Cancer Research DivisionPeter MacCallum Cancer CentreEast MelbourneVicAustralia

2. Sir Peter MacCallum Department of OncologyUniversity of MelbourneParkville Vic Australia

3. Department of PathologyUniversity of MelbourneParkville Vic Australia

4. Department of MedicineSt. Vincent's Hospital, University of MelbourneParkville Vic Australia

5. Department of Biochemistry and Molecular BiologyUniversity of MelbourneParkville Vic Australia

6. Department of Biochemistry and Molecular BiologyMonash UniversityClayton Vic Australia

7. School of Biomedical SciencesUniversity of QueenslandBrisbane Qld Australia

Funder

National Health and Medical Research Council

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.31220

Reference53 articles.

1. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

3. Five‐year overall survival (OS) update from a phase II, open‐label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600‐mutant unresectable or metastatic melanoma (MM);Long GV;J Clin Oncol,2017

4. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

5. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma;Biochemical Pharmacology;2024-08

2. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling;International Journal of Cancer;2024-07-12

3. Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance;Cancer Cell International;2024-03-10

4. Regulation of Cell Cycle Progression through RB Phosphorylation by Nilotinib and AT-9283 in Human Melanoma A375P Cells;International Journal of Molecular Sciences;2024-03-03

5. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma;Oncogene;2023-12-08